title: [5 years neuroblastoma screening in Austria: rate of participation, results and a comparison with other screening areas].
abstract: In late 1990 a screening program for the early detection of neuroblastoma in infants was introduced in Austria. The program is performed on a voluntary basis in collaboration with general pediatricians and practitioners. Filter strips for urine collection are distributed to parents of infants aged seven to nine months on the occasion of a routine check up. The samples are sent to the laboratory by parents and analysed for vanillylmandelic acid (VMA) and homovanillic acid (HVA). Between January 1991 and December 1995 125,201 infants were screened. The compliance rate was 26.8% for Austria, but great differences were seen for different regions (65% in Carinthia, 10% in Vorarlberg). 30 children were admitted to hospital for investigation of repeatedly elevated urine catecholamines. A neuroblastoma was identified in 16 cases. In 12 of these cases at least one unfavorable prognostic factor was present (stage > or = 3, elevated LDH, unfavorable histology, N-myc amplification, di- or tetraploidy). Neuroblastoma screening of infants aged more than six months seems to detect predominantly those tumors which are unlikely to regress spontaneously. The observation of one false negative case, however, demonstrates that neuroblastomas which become clinically manifest at a later date may remain undetected by early screening. Possible advantages of shifting screening to a later age and repeated screening are discussed.
authors.affiliation: Abteilung für Hämatologie und Onkologie, Universitäts-Kinderklinik, Graz.
authors.forename: R
authors.initials: R
authors.lastname: Kerbl
authors.forename: C E
authors.initials: CE
authors.lastname: Urban
authors.forename: R
authors.initials: R
authors.lastname: Ladenstein
authors.forename: C
authors.initials: C
authors.lastname: Schnellauf
authors.forename: C
authors.initials: C
authors.lastname: Sitzwohl
authors.forename: H
authors.initials: H
authors.lastname: Lackner
authors.forename: H
authors.initials: H
authors.lastname: Gleispach
authors.forename: G
authors.initials: G
authors.lastname: Fauler
authors.forename: P F
authors.initials: PF
authors.lastname: Ambros
authors.forename: I M
authors.initials: IM
authors.lastname: Ambros
authors.forename: S
authors.initials: S
authors.lastname: Rumpler
authors.forename: H
authors.initials: H
authors.lastname: Gadner
authors.forename: E
authors.initials: E
authors.lastname: Spuller
authors.forename: G
authors.initials: G
authors.lastname: Höfler
authors.forename: G
authors.initials: G
authors.lastname: Amann
authors.forename: J
authors.initials: J
authors.lastname: Kytir
authors.forename: I
authors.initials: I
authors.lastname: Mutz
mesh_terms: D001317:Austria / Q000453:epidemiology; D003430:Cross-Sectional Studies; D005260:Female; D006719:Homovanillic Acid / Q000652:urine; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D008403:Mass Screening / Q000706:statistics & numerical data*; D009447:Neuroblastoma / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D010342:Patient Acceptance of Health Care; D011379:Prognosis; D011934:Reagent Strips; D014642:Vanilmandelic Acid / Q000652:urine
chemical_list: D011934:Reagent Strips; D014642:Vanilmandelic Acid; D006719:Homovanillic Acid
vernacular_title: Fünf Jahre Neuroblastom-Screening in Osterreich: Beteiligungsrate, Ergebnisse und ein Vergleich mit anderen Screeningregionen.